Bedfont Scientific, a medical device manufacturer in the United Kingdom, receives the green light from the FDA to continue importing to the USA.
Bedfont Scientific, who in 2016 are celebrating two important anniversaries – 40 years in business and 30 years of one of their most successful exports - the Smokerlyzer, are revered as pioneers in the breath analysis market. Their products are available in over 76 countries across the world thanks to their unprecedented network of appointed distributors.
Bedfont have received word from the FDA that they are able to continue importing and selling their medical devices into the USA as usual, after an automatic and temporary interruption to their trade. This pause, which was a result of a paperwork error, was not related to the quality or safety of the products. Bedfont has no issue with this decision or the FDA, and the error in the paperwork was corrected within the 15-day timeframe set by the FDA.
Though a first for Bedfont, they are pleased to say that still, after 40 years of business, no Bedfont product has ever been withdrawn because it failed to meet the FDA's exacting standards. Bedfont will continue to grow their customer base alongside coVita. A long-standing distributor of Bedfont, coVita has played a key role in cultivating Bedfont’s growth in the USA, which is one of Bedfont’s most important and mature markets.
Bedfont Scientific, who in 2016 are celebrating two important anniversaries – 40 years in business and 30 years of one of their most successful exports - the Smokerlyzer, are revered as pioneers in the breath analysis market. Their products are available in over 76 countries across the world thanks to their unprecedented network of appointed distributors.
Bedfont have received word from the FDA that they are able to continue importing and selling their medical devices into the USA as usual, after an automatic and temporary interruption to their trade. This pause, which was a result of a paperwork error, was not related to the quality or safety of the products. Bedfont has no issue with this decision or the FDA, and the error in the paperwork was corrected within the 15-day timeframe set by the FDA.
Though a first for Bedfont, they are pleased to say that still, after 40 years of business, no Bedfont product has ever been withdrawn because it failed to meet the FDA's exacting standards. Bedfont will continue to grow their customer base alongside coVita. A long-standing distributor of Bedfont, coVita has played a key role in cultivating Bedfont’s growth in the USA, which is one of Bedfont’s most important and mature markets.
